Immunome Inc. (IMNM) income statement
IMNMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q1 năm tài chính 2026, quý kết thúc ngày Mar 31, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$16.78−0.40 (-2.33%)
Close on Nov 18, 2026Market cap $1.91BP/E –Yield –
Immunome Inc. income statement
Ratios
Latest available, balances at Mar 31, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -5947.9%
- Net margin
- -5593.8%
- Return on equity, FY2025
- -52.1%
Financial strength
- Current ratio
- 21.68
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 2125.7%
Valuation
- P/E ratio
- –
- Price to sales
- 474.68
- Price to book
- 3.24
- Dividend yield
- –
See a number that looks wrong?